Retatrutide holds the record for weight loss in a Phase 3 trial. But if that is all you know about it, you are missing most of the story. The trials also show it clearing fatty liver, cutting knee-arthritis pain, cleaning up blood fats and possibly protecting the kidneys — effects that go beyond what weight loss alone would explain.
In this video, Dr Kevin Joseph — an obesity-medicine physician — explains why retatrutide works differently, then walks organ by organ through the published data. Watch it first; underneath, we summarise the numbers and sort each claim into proven, promising or early.
Third-party educational video by Dr Kevin Joseph, DO, shared for reference. LA LAB did not produce it and is not affiliated with the channel.
Three switches in one molecule
Semaglutide flips one metabolic switch. Tirzepatide flips two. Retatrutide flips three, once a week:
| Switch | What it does |
|---|---|
| GLP-1 | Slower stomach emptying, less hunger, better blood-sugar control, less fat made in the liver |
| GIP | Insulin released only when blood sugar is high, better fat handling, lower inflammation — and retatrutide hits it roughly nine times harder than the body's own hormone |
| Glucagon | More calories burned, the liver burns fat instead of storing it, and makes less new fat |
The glucagon switch is the one that changes everything. Doctors avoided it for years because glucagon raises blood sugar. Switched on gently alongside GLP-1 and GIP, that problem is covered — and what is left is a liver that burns its own fat. You can see it in trial blood work: a fat-burning marker (beta-hydroxybutyrate) rises two to three-fold, and the bigger the rise, the more liver fat is lost. Its long half-life (about six days) is why one injection a week is enough.
The weight numbers, briefly
| Trial | Dose | Average weight loss |
|---|---|---|
| Phase 2 · 48 weeks | 8 mg | ~23% |
| Phase 2 · 48 weeks | 12 mg | ~24% — and still falling |
| TRIUMPH-4 · 68 weeks | 9 mg | ~26% |
| TRIUMPH-4 · 68 weeks | 12 mg | ~29% — a Phase 3 record |
The liver: the headline result
Fatty liver disease (MASLD) now affects well over a third of adults, has almost no approved treatment, and is one of the fastest-growing reasons for liver transplants. In a 2024 Nature Medicine study of 98 people with at least 10% liver fat, retatrutide cut liver fat by:
| Dose | 24 weeks | 48 weeks |
|---|---|---|
| 1 mg | −43% | |
| 4 mg | −57% | |
| 8 mg | −81% | −82% |
| 12 mg | −82% | −86% |
Most striking of all: at 48 weeks, 93% of people on the top dose had a normal liver again (under 5% fat). The study did not take biopsies, so it cannot yet prove scarring reverses — markers of scarring did fall, and the 4,500-person SYNERGY-OUTCOMES trial is designed to settle it.
Knee arthritis
Every extra kilogram adds about four kilograms of force on the knee with each step, and body fat also releases chemicals that wear cartilage directly. In TRIUMPH-4's study of 445 people with obesity and knee arthritis, knee pain at 12 mg fell by about 75% — more than researchers expected from weight loss alone, which hints at an anti-inflammatory effect inside the joint.
The heart and blood fats
Data from 338 people over 48 weeks showed the artery-clogging profile cleaning up:
| Marker | Change (up to) |
|---|---|
| Triglycerides | −40% |
| ApoC3 | −36% |
| Non-HDL cholesterol | −27% |
| ApoB | −24% |
It specifically reduced the small, dense LDL particles that burrow into artery walls. That is a strong early signal; the long-term heart-outcomes trial will show whether it means fewer heart attacks.
The kidneys
A pooled analysis of two trials found kidney filtration improved at the higher doses, and protein leaking into the urine — an early warning sign of kidney damage — dropped at the top dose. A dedicated trial (TRANSCEND-CKD) is now running.
Sleep apnoea and the brain
Tirzepatide roughly halved sleep-apnoea events and is approved for it overseas; retatrutide is being tested for the same and is expected to do at least as well. The brain is the newest frontier: rat studies in 2026 showed better memory and less brain inflammation, but there are no human brain studies yet — this is the least proven part of the story.
The evidence scorecard
| Claim | Evidence | Where it comes from |
|---|---|---|
| Weight loss | Proven | Phase 2 and TRIUMPH-4 (Phase 3) — up to ~29% |
| Liver fat cleared | Proven | Nature Medicine 2024 — 93% normal at 12 mg |
| Knee arthritis pain | Proven | TRIUMPH-4 — ~75% less pain at 12 mg |
| Blood fats (ApoB, triglycerides) | Proven | 48-week lipid data, 338 people |
| Liver scarring reversed | Promising | Scarring markers fell; biopsy trial reports ~2029–30 |
| Kidney protection | Promising | Pooled post-hoc data; TRANSCEND-CKD running |
| Fewer heart attacks | Promising | Outcomes trial still running |
| Brain / memory | Early | Rat studies only |
Retatrutide is still investigational — not approved by SAHPRA, the FDA or any regulator — and the big outcome trials are still running. TRIUMPH-4 also flagged a nerve side effect called dysaesthesia (unusual skin sensations such as tingling or burning). Our Retatrutide guide covers the safety signals and why the dose is stepped up slowly and capped at 12 mg a week.
Related reading
See the companion post, Tirzepatide beyond weight loss, the Retatrutide masterclass for the reconstitution maths, and microdosing Tirzepatide and Retatrutide.